Advertisement
BRKR vs MEDP
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Medpace Holdings, Inc. (MEDP) Stock Comparison
Key Takeaways
- Both BRKR and MEDP operate in the healthcare sector, with BRKR focusing on scientific instruments and MEDP on clinical research services.
- BRKR has shown strong recent momentum, with shares up approximately 15% over recent weeks amid new product collaborations.
- MEDP exhibits steadier long-term growth, supported by robust revenue increases and lower debt levels.
- Tickeron's analysis rates BRKR as a short-term buy due to bullish technical indicators, while MEDP holds stronger long-term value metrics.
- BRKR trades at a higher P/E ratio (74.88) compared to MEDP (34.58), reflecting differing growth expectations.
- Market caps differ notably: BRKR at $6.26B versus MEDP at $15.09B.
Introduction
This stock comparison examines BRKR and MEDP, two healthcare players offering distinct exposure within life sciences. BRKR provides analytical instruments essential for research, while MEDP, a contract research organization (CRO), supports drug and device development trials. Investors seeking diversified healthcare bets or traders eyeing momentum shifts may find value in evaluating their relative performance, sector dynamics, and AI-driven insights amid evolving market conditions.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops, manufactures, and distributes scientific instruments, analytical solutions, and diagnostics for life sciences, pharmaceuticals, and biotechnology applications. The company operates in the medical devices industry, with segments focused on mass spectrometry, imaging, and microscopy tools.
In recent market activity, BRKR shares have exhibited volatility but regained positive momentum, rising about 15% over recent weeks. This uptrend follows Q4 FY25 results showing $977.2 million in revenue and EPS of $0.59, alongside new developments like an AFM-IR semiconductor collaboration with Imec and NMR portfolio expansions. Year-to-date, the stock has climbed 12.63%, outperforming the S&P 500, driven by product innovation sentiment despite margin pressures from helium costs.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) is a CRO providing full-service clinical research for drug and medical device development across North America, Europe, and beyond. It caters to small- and mid-sized biotech firms with end-to-end trial management.
Recent weeks have seen MEDP maintain steady performance amid anticipation for Q1 2026 earnings. The stock has shown resilience, with weekly gains aligning closely with peers, supported by prior Q4 revenue beats and ongoing demand for clinical services. Broader strength stems from a 75% rise over the past year, though YTD figures reflect market caution. Factors influencing sentiment include lower debt exposure and higher EBITDA relative to peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from a library of 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. These 25 featured bots excel in current market conditions, boasting impressive stats like annualized returns ranging from +34% to +101%, win rates of 56-88%, profit factors up to 6.94, and profit-to-drawdown ratios exceeding 8 in many cases. Spanning strategies from swing trading on 60-minute timeframes to scalping semiconductors on 5-minute charts, they cover diverse sectors including industrials, energy, and tech leaders like NVDA and SOXL. Explore these bots to align automated trading with your style and market outlook.
Head-to-Head Comparison
BRKR’s business model centers on hardware sales of high-tech instruments, exposing it to R&D spending cycles in pharma and biotech, while MEDP relies on service contracts for clinical trials, benefiting from steady pipeline backlogs but sensitive to trial delays.
Growth drivers differ: BRKR leverages innovation catalysts like new spectroscopy tools, whereas MEDP capitalizes on outsourcing trends. Recent momentum favors BRKR short-term (TA score 6 bullish), but MEDP shows superior long-term value with lower P/E, debt, and better FA score.
Risk factors include BRKR’s higher leverage (debt $2.01B) and helium dependencies versus MEDP’s minimal debt ($114M). Sector exposure overlaps in life sciences, but sentiment tilts toward BRKR on technical rebound and MEDP on profitability stability.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors BRKR with a "Buy" rating over MEDP’s "Hold," citing stronger short-term technical indicators (TA score 6 vs. 5), higher relative volume, and recent momentum amid product catalysts. While MEDP edges long-term on fundamentals like lower risk and valuation, BRKR appears better positioned for near-term upside in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Hold and MEDP is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while MEDP’s TA Score has 5 bullish TA indicator(s).
- BRKR’s TA Score: 4 bullish, 5 bearish.
- MEDP’s TA Score: 5 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -1.15% price change this week, while MEDP (@Medical Specialties) price change was +2.58% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +14.19%. For the same industry, the average monthly price growth was +10.26%, and the average quarterly price growth was -6.43%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +7.70%. For the same industry, the average monthly price growth was +8.34%, and the average quarterly price growth was +1.99%.
Reported Earning Dates
BRKR is expected to report earnings on Aug 05, 2026.
MEDP is expected to report earnings on Jul 22, 2026.
Industries' Descriptions
@Medical/Nursing Services (+14.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+7.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | MEDP | BRKR / MEDP | |
| Capitalization | 8.9B | 14.6B | 61% |
| EBITDA | 306M | 591M | 52% |
| Gain YTD | 24.345 | -8.699 | -280% |
| P/E Ratio | 74.88 | 28.67 | 261% |
| Revenue | 3.46B | 2.68B | 129% |
| Total Cash | N/A | 653M | - |
| Total Debt | 1.67B | 122M | 1,370% |
BRKR | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 32 | |
SMR RATING 1..100 | 92 | 15 | |
PRICE GROWTH RATING 1..100 | 39 | 47 | |
P/E GROWTH RATING 1..100 | 5 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (49) in the Medical Specialties industry is in the same range as MEDP (77) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (32) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (100) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (92) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
BRKR's Price Growth Rating (39) in the Medical Specialties industry is in the same range as MEDP (47) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to MEDP’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as MEDP (32) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to MEDP’s over the last 12 months.
| BRKR | MEDP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 76% | N/A |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 74% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 76% |
| Advances ODDS (%) | 27 days ago 69% | 1 day ago 75% |
| Declines ODDS (%) | 2 days ago 72% | 8 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 74% |
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | +6.04% | ||
| A - BRKR | 78% Closely correlated | +3.92% | ||
| MTD - BRKR | 75% Closely correlated | +4.02% | ||
| WAT - BRKR | 68% Closely correlated | +3.35% | ||
| RVTY - BRKR | 68% Closely correlated | +5.74% | ||
| TMO - BRKR | 66% Loosely correlated | +4.87% | ||
More | ||||
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with IQV. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | +8.30% | ||
| IQV - MEDP | 65% Loosely correlated | +8.37% | ||
| CRL - MEDP | 52% Loosely correlated | +8.31% | ||
| TMO - MEDP | 46% Loosely correlated | +4.87% | ||
| BRKR - MEDP | 43% Loosely correlated | +6.04% | ||
| RVTY - MEDP | 39% Loosely correlated | +5.74% | ||
More | ||||